Human papillomavirus vaccine coverage in Rwanda: A population-level analysis by birth cohort
2020/04/24 by Félix Sayinzoga, Felix Sayinzoga, M. Chantal Umulisa +4 · 26 citations
Medicine · Social Sciences · #Cervical Cancer and HPV Research #Vaccine Coverage and Hesitancy #Global Cancer Incidence and Screening
paper · doi:10.1016/j.vaccine.2020.04.021
Abstract
BACKGROUND: In 2011, Rwanda became the first African nation to implement a national human papillomavirus (HPV) vaccination program, conceived to protect girls aged <15 years (i.e. born ≥1997). After an initial school-grade-targeted catch-up campaign, there was a transition to routine vaccination of 12 year-olds only. We aimed to produce population-level vaccine coverage estimates. METHODS: The Rwandan Expanded Program on Immunization (EPI) collected data on number of eligible girls and HPV vaccines delivered, stratified by calendar year (2011-2018), girl's age, district and vaccination round. HPV vaccine coverage was estimated by birth cohort (reconstituted using calendar year and age), as a proportion of (1) eligible target, and (2) the 2012 Rwandan census population. RESULTS: 1,156,863 girls received first dose of HPV vaccine between 2011 and 2018, corresponding to 98% of the eligible target. Median vaccination age was 15 years (interquartile range [IQR] 13-16) in 2011-2013 (school grade-targeted catch-up), 13 years (IQR 12-14) in 2014 (transition) and 12 years in 2015-2018 (routine). Population-level coverage versus the census increased from 10 to 40% for girls born in 1993-1995 (median vaccination age = 17 years) to 50-65% for 1996-2000 birth cohorts (14 years), and 80-90% for 2001-2006 birth cohorts (12 years). Coverage trends were similar across provinces and in the capital, Kigali. Second and third round coverage suggested most vaccinated girls completed their recommended dosing regimen (which reduced from 3 to 2 doses in 2015). CONCLUSIONS: Birth cohorts provide a clear picture of population-level HPV vaccine coverage after a pragmatic catch-up campaign, particularly in Rwanda where eligible school grades included wide age ranges. Whilst the catch-up campaign resulted in some coverage gaps in out-of-school teenagers, coverage remains high in cohorts routinely targeted as 12 year-olds.
Cited by
- HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019
- State of Cancer Control in Rwanda: Past, Present, and Future Opportunities. [europepmc]
- National implementation of HPV vaccination programs in low-resource countries: Lessons, challenges, and future prospects. [europepmc]
- Healthcare provider challenges to early detection of cervical cancer at primary healthcare level in Rwanda. [europepmc]
- The impact of HPV vaccination beyond cancer prevention: effect on pregnancy outcomes. [europepmc]
- High-burden Cancers in Middle-income Countries: A Review of Prevention and Early Detection Strategies Targeting At-risk Populations. [europepmc]
- Human Papillomavirus Vaccination in South Africa: Programmatic Challenges and Opportunities for Integration With Other Adolescent Health Services? [europepmc]
- Cancer in sub-Saharan Africa: a Lancet Oncology Commission. [europepmc]
- Impact of Parental Knowledge and Beliefs on HPV Vaccine Hesitancy in Kenya-Findings and Implications. [europepmc]
- Cancer service delivery and the impact of the COVID-19 pandemic in sub-Saharan Africa: a scoping review. [europepmc]
- Human papillomavirus vaccination in low- and middle-income countries: progression, barriers, and future prospective. [europepmc]
- Understanding HPV Vaccination Policymaking in Rwanda: A Case of Health Prioritization and Public-Private-Partnership in a Low-Resource Setting. [europepmc]
- HPV vaccination in Africa in the COVID-19 era: a cross-sectional survey of healthcare providers' knowledge, training, and recommendation practices. [europepmc]
- Improving HPV Vaccination Uptake Among Adolescents in Low Resource Settings: Sociocultural and Socioeconomic Barriers and Facilitators. [europepmc]
- The acceptance of COVID-19 vaccines in Rwanda: a cross-sectional study. [europepmc]
- The barriers to cervical cancer screening for urban and rural populations in Rwanda. [europepmc]
- Optimization and analytical validation of the Allplex HPV28 genotyping assay for use in first-void urine samples. [europepmc]
- The Global Fund, Cervical Cancer, and HPV infections: what can low- and middle-income countries do to accelerate progress by 2030? [europepmc]
- Prevalence of Human Papillomavirus and Genotype Correlation with Cervical Lesions at the University Teaching Hospital of Kigali. [europepmc]
- Multilevel Targets for Promoting Pediatric HPV Vaccination: A Systematic Review of Parent-Centered, Provider-Centered, and Practice-Centered Interventions in HIC and LMIC Settings. [europepmc]
- HPV Vaccine Delivery Strategies to Reach Out-of-School Girls in Low- and Middle-Income Countries: A Narrative Review. [europepmc]
- Exploring awareness, attitudes and clinical practices of Ukrainian health professionals regarding human papillomavirus and vaccination: a qualitative study. [europepmc]
- Gender-neutral human papillomavirus vaccination: an equitable and cost-effective public health investment. [europepmc]
- Knowledge, attitudes, and practices of cervical cancer preventive services among mothers living with HIV in Lagos, Nigeria: a cross-sectional study. [europepmc]
- Geographic and demographic patterns of cervical cancer in Africa using GLOBOCAN 2022. [europepmc]
- Determinants of human papillomavirus vaccine non-uptake among adolescent girls in Ethiopia: evidence from National Immunization Survey. [europepmc]
Related